Correction to: Sig Transduct Target Therapy https://doi.org/10.1038/s41392-021-00688-z, published online 14 July 2021

After online publication of the article1, the authors noticed one inadvertent mistake in Fig. 5a that needs to be corrected. In detail, the pathological picture of PBS group in Fig. 5a is inadvertently duplicated as the image of PBS group in Fig. 7b in the main text. This duplication is a result of errors in figure assembly, and the correct Fig. 5 is provided as follows. The key findings of the article are not affected by these corrections.

Fig. 5
figure 5

PSLs ameliorate ConA-induced ALI and LPS-induced lung injury. a Mice were intravenously injected with 12 mg/kg ConA, followed by treatment with PBS, PCLs, or PSLs. Representative images of liver histopathology with H&E staining in each group. Scale bar represents 200 μm. b–d Quantitative analysis of necrosis area (b), TUNEL-positive cells (c), and serum ALT and AST levels (d) in mice with PBS, PCLs, or PSLs treatment. n = 5. e Survival of 25 mg/kg ConA-injected mice treated with PBS, PCLs, and PSLs. n = 10. f, g The levels of IL-6, IFN-γ, and TNF-α in serum (f) and IL-10, HGF in hepatic tissues (g) were determined by ELISA. n = 3~5 in each group. h Representative images of lung histopathology 72 h after LPS administration. Scale bar represents 200 μm. i Histopathology score of lung sections in each group. n = 5 in each group. Data are represented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001

Full size image